SG11201802665VA - Ferroportin inhibitors - Google Patents
Ferroportin inhibitorsInfo
- Publication number
- SG11201802665VA SG11201802665VA SG11201802665VA SG11201802665VA SG11201802665VA SG 11201802665V A SG11201802665V A SG 11201802665VA SG 11201802665V A SG11201802665V A SG 11201802665VA SG 11201802665V A SG11201802665V A SG 11201802665VA SG 11201802665V A SG11201802665V A SG 11201802665VA
- Authority
- SG
- Singapore
- Prior art keywords
- ferroportin inhibitors
- ferroportin
- inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/14—Radicals substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP15191179 | 2015-10-23 | ||
EP15191176 | 2015-10-23 | ||
PCT/EP2016/075305 WO2017068089A2 (en) | 2015-10-23 | 2016-10-21 | Novel ferroportin inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201802665VA true SG11201802665VA (en) | 2018-05-30 |
Family
ID=57178421
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201802480YA SG11201802480YA (en) | 2015-10-23 | 2016-10-21 | Novel ferroportin inhibitors |
SG11201802665VA SG11201802665VA (en) | 2015-10-23 | 2016-10-21 | Ferroportin inhibitors |
SG10202005377VA SG10202005377VA (en) | 2015-10-23 | 2016-10-21 | Novel ferroportin inhibitors |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201802480YA SG11201802480YA (en) | 2015-10-23 | 2016-10-21 | Novel ferroportin inhibitors |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10202005377VA SG10202005377VA (en) | 2015-10-23 | 2016-10-21 | Novel ferroportin inhibitors |
Country Status (22)
Country | Link |
---|---|
US (5) | US10364239B2 (en) |
EP (2) | EP3364967A2 (en) |
JP (3) | JP6710754B2 (en) |
KR (1) | KR102352829B1 (en) |
CN (2) | CN114668761A (en) |
AU (3) | AU2016342310B2 (en) |
BR (1) | BR112018007977B1 (en) |
CA (2) | CA3002418C (en) |
CL (1) | CL2018001031A1 (en) |
CO (1) | CO2018004165A2 (en) |
HK (1) | HK1252543A1 (en) |
IL (2) | IL258158B2 (en) |
JO (1) | JO3780B1 (en) |
MA (1) | MA44474A (en) |
MX (2) | MX2018004882A (en) |
NZ (1) | NZ740675A (en) |
PE (1) | PE20181496A1 (en) |
PH (1) | PH12018500769A1 (en) |
SG (3) | SG11201802480YA (en) |
TW (1) | TWI722031B (en) |
UA (1) | UA123219C2 (en) |
WO (2) | WO2017068090A1 (en) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2968443B1 (en) | 2013-03-15 | 2021-09-29 | Protagonist Therapeutics, Inc. | Hepcidin analogues and uses thereof |
AU2016342310B2 (en) * | 2015-10-23 | 2020-08-27 | Vifor (International) Ag | Novel ferroportin inhibitors |
JOP20180036A1 (en) * | 2017-04-18 | 2019-01-30 | Vifor Int Ag | Novel ferroportin-inhibitor salts |
CN108314687A (en) * | 2017-12-27 | 2018-07-24 | 重庆文理学院 | 1,2- dihydrobenzos [4,5] imidazo [1,2-a] pyrazine -3(4H)The synthesis of -one derivative |
CA3089868A1 (en) | 2018-02-08 | 2019-08-15 | Protagonist Therapeutics, Inc. | Conjugated hepcidin mimetics |
WO2019213016A1 (en) * | 2018-04-30 | 2019-11-07 | The Children's Hospital Of Philadelphia | Methods of improving anemias by combining agents |
US11286243B2 (en) | 2018-12-13 | 2022-03-29 | Global Blood Therapeutics, Inc. | Ferroportin inhibitors and methods of use |
TW202102478A (en) | 2019-04-01 | 2021-01-16 | 瑞士商威佛(國際)股份有限公司 | Novel iron chelators |
CN114302882A (en) * | 2019-07-19 | 2022-04-08 | 威佛(国际)股份公司 | Ferroportin inhibitor for treating transfusion-dependent BETA-thalassemia (TDT) |
EP3999060A1 (en) * | 2019-07-19 | 2022-05-25 | Vifor (International) Ag | Ferroportin-inhibitors for the use in the prevention and treatment of kidney injuries |
EP3782702A1 (en) * | 2019-08-21 | 2021-02-24 | AC BioScience SA | Compounds and use thereof for the treatment of infectious diseases and cancer |
CN114765955A (en) | 2019-10-22 | 2022-07-19 | 威佛(国际)股份公司 | Methods and compositions for treating sickle cell disease with an iron transporter inhibitor (VIT-2763) |
CN115362154A (en) | 2020-03-24 | 2022-11-18 | 威佛(国际)股份公司 | Preparation method of ferroportin inhibitor |
GB202012969D0 (en) * | 2020-08-19 | 2020-09-30 | Univ Of Oxford | Inhibitor compounds |
JP2024504349A (en) | 2021-01-20 | 2024-01-31 | ビフォー (インターナショナル) エージー | Ferroportin inhibitors for use in the treatment of myelodysplastic syndromes (MDS) |
WO2022173818A1 (en) * | 2021-02-09 | 2022-08-18 | University Of Virginia Patent Foundation | Use of biliverdin reductase b inhibitors to allow malaria eradication in patients with g6pd deficiency |
TW202304896A (en) | 2021-04-22 | 2023-02-01 | 瑞士商威佛(國際)股份有限公司 | Modified ferroportin inhibitors |
AR127105A1 (en) | 2021-09-21 | 2023-12-20 | Vifor Int Ag | N-SUBSTITUTED FERROPORTIN INHIBITORS |
WO2024083980A1 (en) | 2022-10-21 | 2024-04-25 | Vifor (International) Ag | Bicyclic ferroportin inhibitors |
Family Cites Families (51)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB937879A (en) * | 1959-12-24 | 1963-09-25 | Ciba Ltd | New pyrazole-carboxylic acid hydrazides |
TW533205B (en) | 1996-06-25 | 2003-05-21 | Novartis Ag | Substituted 3,5-diphenyl-l,2,4-triazoles and their pharmaceutical composition |
US5922761A (en) | 1996-09-06 | 1999-07-13 | Medinox, Inc. | Methods for in vivo reduction of iron levels and compositions useful therefor |
AR009655A1 (en) | 1996-12-10 | 2000-04-26 | Novartis Ag | A PARENTERALLY INJECTABLE COMPOSITION, A METHOD FOR ITS PREPARATION, METHODS FOR THE TREATMENT OF DISEASES, A CRYSTAL MODIFICATION OF 1-DECANSULFONATE OF DESPHERRIOXAMINE, ITS USE, A PROCESS FOR THE PRODUCTION OF SUCH CRYSTAL MODIFICATION AND A PREPARATION FOR PHARMACEUTICAL PREPARATION |
EP0946587A2 (en) * | 1996-12-16 | 1999-10-06 | Fujisawa Pharmaceutical Co., Ltd. | New amide compounds |
WO2000056724A1 (en) * | 1999-03-22 | 2000-09-28 | The Board Of Governors For Higher Education, State Of Rhode Island And Providence Plantations | Oxazole and thiazole combinatorial libraries |
EP1074254A3 (en) | 1999-07-20 | 2002-09-11 | MEDIS S.r.l. Medical Infusion Systems | Use of plant polyphenols with vitamines for treating iron overload |
EP1072265A1 (en) | 1999-07-20 | 2001-01-31 | MEDIS S.r.l. Medical Infusion Systems | Use of plant polyphenols for treating iron overload |
JP2004508421A (en) | 2000-09-15 | 2004-03-18 | アノーメッド インコーポレイティド | Chemokine receptor binding heterocyclic compounds |
DE10063173A1 (en) * | 2000-12-18 | 2002-06-20 | Merck Patent Gmbh | Urea and urethane derivatives |
EP1430032A2 (en) * | 2001-09-24 | 2004-06-23 | Elan Pharmaceuticals, Inc. | Substituted amides for the treatment of neurological disorders |
US20030109548A1 (en) | 2001-11-09 | 2003-06-12 | Royt Paulette W. | Compositions and methods of treating iron excess |
US6933308B2 (en) | 2002-12-20 | 2005-08-23 | Bristol-Myers Squibb Company | Aminoalkyl thiazole derivatives as KCNQ modulators |
AU2004260831A1 (en) | 2003-07-21 | 2005-02-10 | Laboratoires Serono Sa | Aryl dicarboxamides |
WO2005014576A1 (en) | 2003-08-12 | 2005-02-17 | Takeda Pharmaceutical Company Limited | Isoquinolinone derivative, process for producing the same and use thereof |
DE10356409B4 (en) | 2003-11-28 | 2006-12-28 | Biofrontera Discovery Gmbh | New drug oxacheline and derivatives |
FR2870271B1 (en) | 2004-05-11 | 2008-03-14 | Bruno Merand | METHOD FOR CONSTRUCTING WOODEN HOUSE AND MEANS FOR IMPLEMENTING THE METHOD |
WO2006040646A1 (en) | 2004-10-14 | 2006-04-20 | Pfizer, Inc. | Benzimidazole or indole amides as inhibitors of pin1 |
JP2008007405A (en) | 2004-12-07 | 2008-01-17 | Takeda Chem Ind Ltd | Carboxamide derivative |
EP1871770A1 (en) * | 2005-04-22 | 2008-01-02 | Kalypsys, Inc. | Ortho-terphenyl inhibitors of p38 kinase and methods of treating inflammatory disorders |
WO2006127550A1 (en) | 2005-05-23 | 2006-11-30 | Merck & Co., Inc. | Proline bis-amide orexin receptor antagonists |
WO2006132436A1 (en) * | 2005-06-08 | 2006-12-14 | Japan Tobacco Inc. | Heterocyclic compound |
WO2007022258A1 (en) * | 2005-08-17 | 2007-02-22 | Schering Corporation | Novel high affinity thiophene-based and furan-based kinase ligands |
AU2006316087B2 (en) | 2005-11-21 | 2011-03-10 | Shionogi & Co., Ltd. | Heterocyclic compound having inhibitory activity on 11-beta-hydroxysteroid dehydrogenase type I |
JP2009525955A (en) | 2006-01-13 | 2009-07-16 | タケダ サン ディエゴ インコーポレイテッド | Histone deacetylase inhibitor |
JP5178738B2 (en) * | 2006-12-20 | 2013-04-10 | メルク・シャープ・アンド・ドーム・コーポレーション | Novel JNK inhibitor |
AR065628A1 (en) | 2007-03-07 | 2009-06-17 | Xenon Pharmaceuticals Inc | TRICYCLE COMPOUNDS OF USEFULNESS IN THE TREATMENT OF IRON DISEASE IN THE ORGANISM |
AR065785A1 (en) | 2007-03-19 | 2009-07-01 | Xenon Pharmaceuticals Inc | BIARETO AND BIHETEROARILE COMPOUNDS OF UTILITY IN THE TREATMENT OF IRON DISORDERS |
JPWO2008123093A1 (en) | 2007-03-20 | 2010-07-15 | 明治製菓株式会社 | Preventive or therapeutic agent for iron overload |
CL2008000793A1 (en) | 2007-03-23 | 2008-05-30 | Xenon Pharmaceuticals Inc | COMPOUNDS DERIVED FROM DIHYDROINDAZOL; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUNDS; AND ITS USE TO TREAT AN IRON DISORDER. |
EP2133339A4 (en) * | 2007-03-28 | 2010-04-21 | Santen Pharmaceutical Co Ltd | Novel (2-aminophenyl)pyridinecarboxamide derivative having urea structure |
WO2008151288A2 (en) | 2007-06-05 | 2008-12-11 | Xenon Pharmaceuticals Inc. | Aromatic and heteroaromatic compounds useful in treating iron disorders |
US20120094974A1 (en) | 2008-06-17 | 2012-04-19 | Wei Chen | Smoothened receptor modulators |
WO2010020556A1 (en) * | 2008-08-22 | 2010-02-25 | Evotec Neurosciences Gmbh | New bradykinin b1 antagonists |
UA103634C2 (en) | 2008-09-26 | 2013-11-11 | Берингер Ингельхайм Интернациональ Гмбх | Azaindazole compounds as ccr1 receptor antagonists |
RU2011123647A (en) | 2008-11-10 | 2012-12-20 | Вертекс Фармасьютикалз Инкорпорейтед | COMPOUNDS USEFUL AS ATR KINASE INHIBITORS |
WO2010059606A2 (en) | 2008-11-19 | 2010-05-27 | Schering Corporation | Inhibitors of diacylglycerol acyltransferase |
US9328140B2 (en) | 2008-12-05 | 2016-05-03 | The Regents Of The University Of California | Modified mini-hepcidin peptides and methods of using thereof |
WO2010078408A1 (en) * | 2008-12-30 | 2010-07-08 | Biogen Idec Ma Inc. | Heteroaryl compounds useful as raf kinase inhibitors |
AR077958A1 (en) * | 2009-08-27 | 2011-10-05 | Vifor Int Ag | ANTOGONIST QUINOXALINONES OF HEPCIDINE |
TW201111379A (en) * | 2009-09-09 | 2011-04-01 | Vifor Int Ag | Novel thiazole-and oxazole-hepcidine-antagonists |
US9586914B2 (en) | 2011-11-07 | 2017-03-07 | The University Of Queensland | Modulators of C3a receptors |
EP2620142A1 (en) | 2012-01-27 | 2013-07-31 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Hedgehog signaling pathway involved in energy metabolism |
WO2013142258A1 (en) | 2012-03-22 | 2013-09-26 | Nanotherapeutics, Inc. | Compositions and methods for oral delivery of encapsulated diethylenetriaminepentaacetate particles |
US9193723B2 (en) * | 2012-05-11 | 2015-11-24 | Abbvie Inc. | NAMPT inhibitors |
CN103508957B (en) * | 2012-06-25 | 2017-02-08 | 中国科学院上海药物研究所 | Hydroxyethyl pyrazole compound or aminoethyl pyrazole compound, preparation method and use thereof |
AR097279A1 (en) | 2013-08-09 | 2016-03-02 | Actelion Pharmaceuticals Ltd | DERIVATIVES OF BENZIMIDAZOLIL-METIL UREA AS ALX RECEIVER AGONISTS |
WO2015051362A1 (en) * | 2013-10-04 | 2015-04-09 | Illinois Institute Of Technology | Multifunctional chelators, complexes, and compositions thereof, and methods of using same |
WO2015069660A2 (en) | 2013-11-05 | 2015-05-14 | New York Blood Center, Inc. | Methods and compositions for increasing hepcidin expression using modified iron binding/releasing transferrin |
AU2014352780A1 (en) | 2013-11-22 | 2016-06-09 | University Of Florida Research Foundation, Inc. | Desferrithiocin analogs and uses thereof |
AU2016342310B2 (en) * | 2015-10-23 | 2020-08-27 | Vifor (International) Ag | Novel ferroportin inhibitors |
-
2016
- 2016-10-21 AU AU2016342310A patent/AU2016342310B2/en active Active
- 2016-10-21 CO CONC2018/0004165A patent/CO2018004165A2/en unknown
- 2016-10-21 JP JP2018520089A patent/JP6710754B2/en active Active
- 2016-10-21 EP EP16784510.6A patent/EP3364967A2/en active Pending
- 2016-10-21 EP EP16797462.5A patent/EP3365339A1/en active Pending
- 2016-10-21 KR KR1020187011524A patent/KR102352829B1/en active IP Right Grant
- 2016-10-21 BR BR112018007977-4A patent/BR112018007977B1/en active IP Right Grant
- 2016-10-21 UA UAA201805740A patent/UA123219C2/en unknown
- 2016-10-21 PE PE2018000572A patent/PE20181496A1/en unknown
- 2016-10-21 AU AU2016342309A patent/AU2016342309B2/en active Active
- 2016-10-21 SG SG11201802480YA patent/SG11201802480YA/en unknown
- 2016-10-21 WO PCT/EP2016/075306 patent/WO2017068090A1/en active Application Filing
- 2016-10-21 MA MA044474A patent/MA44474A/en unknown
- 2016-10-21 CN CN202210353448.6A patent/CN114668761A/en active Pending
- 2016-10-21 CA CA3002418A patent/CA3002418C/en active Active
- 2016-10-21 JP JP2018520090A patent/JP6810988B2/en active Active
- 2016-10-21 MX MX2018004882A patent/MX2018004882A/en unknown
- 2016-10-21 US US15/769,148 patent/US10364239B2/en active Active
- 2016-10-21 CA CA3002416A patent/CA3002416C/en active Active
- 2016-10-21 CN CN201680061941.3A patent/CN108290878B/en active Active
- 2016-10-21 WO PCT/EP2016/075305 patent/WO2017068089A2/en active Application Filing
- 2016-10-21 NZ NZ740675A patent/NZ740675A/en unknown
- 2016-10-21 TW TW105134089A patent/TWI722031B/en active
- 2016-10-21 SG SG11201802665VA patent/SG11201802665VA/en unknown
- 2016-10-21 US US15/768,025 patent/US10738041B2/en active Active
- 2016-10-21 SG SG10202005377VA patent/SG10202005377VA/en unknown
- 2016-10-23 JO JOP/2016/0229A patent/JO3780B1/en active
-
2018
- 2018-03-15 IL IL258158A patent/IL258158B2/en unknown
- 2018-03-15 IL IL258159A patent/IL258159B/en unknown
- 2018-04-06 PH PH12018500769A patent/PH12018500769A1/en unknown
- 2018-04-20 CL CL2018001031A patent/CL2018001031A1/en unknown
- 2018-04-20 MX MX2021015106A patent/MX2021015106A/en unknown
- 2018-09-14 HK HK18111856.0A patent/HK1252543A1/en unknown
-
2019
- 2019-06-12 US US16/438,596 patent/US11001579B2/en active Active
-
2020
- 2020-05-27 JP JP2020091830A patent/JP6967112B2/en active Active
- 2020-11-24 AU AU2020277121A patent/AU2020277121C1/en active Active
- 2020-12-03 US US17/110,465 patent/US11066399B2/en active Active
-
2021
- 2021-06-07 US US17/340,692 patent/US20220363675A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL287113A (en) | Smyd inhibitors | |
HK1252543A1 (en) | Novel ferroportin inhibitors | |
HK1243326A1 (en) | Bromodomain inhibitors | |
IL260217B (en) | Lsd1 inhibitors | |
HK1244785A1 (en) | TGF-β INHIBITORS | |
HK1243415A1 (en) | Bromodomain inhibitors | |
IL248895A0 (en) | Phosphatidylinositol -kinase inhibitors | |
GB201521059D0 (en) | Inhibitors of metallo-beta-lactamases | |
IL265139B (en) | Dopamine-b-hydroxylase inhibitors | |
HK1243948A1 (en) | Bromodomain inhibitor | |
ZA201907136B (en) | Ip6k inhibitors | |
IL294381B1 (en) | Pcna inhibitors | |
GB201612860D0 (en) | Inhibitors | |
GB201501004D0 (en) | Inhibitors | |
HK1250926A1 (en) | Inhibitors and their uses | |
IL274550A (en) | Dopamine-b-hydroxylase inhibitors | |
GB201520949D0 (en) | Inhibitors | |
GB201721465D0 (en) | Inhibitors | |
GB201720189D0 (en) | Dopamine-B-hydroxylase inhibitors | |
GB201519381D0 (en) | Kinase inhibitors | |
GB201519382D0 (en) | Kinase inhibitors | |
GB201505971D0 (en) | Inhibitors and their uses | |
GB201505975D0 (en) | Inhibitors and their uses | |
GB201418154D0 (en) | Inhibitors |